Sanofi Completes Vicebio Acquisition to Add Respiratory Vaccine Candidate
MT Newswires Live
Dec 04
Sanofi (SNY) said Thursday it has completed its acquisition of Vicebio, adding an early-stage respiratory virus vaccine program and related design technology.
The deal brings in a combination vaccine candidate targeting respiratory syncytial virus and human metapneumovirus, along with Vicebio's Molecular Clamp platform, the company said.
The program is expected to broaden Sanofi's respiratory vaccine portfolio and will also add a non-mRNA option to Sanofi's pipeline for RSV and HMPV virus treatment, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.